Citations

Showing 10 of 108152 citations.

Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways
Kleinstern, Geffen , Yan, Huihuang , Berndt, Sonja I. , Ghesquières, Hervé , McKay, James , Wang, Sophia , Nieters, Alexandra, Ye, Yuanqing , Monnereau, Alain , Brooks‐Wilson, Angela , Lan, Qing , Melbye, Mads , Jackson, Rebecca D. , Purdue, Mark P. , Vajdic, Claire M. , Vermeulen, Roel , Cocco, Pier Luigi, Birmann, Brenda M. , Zeleniuch‐Jacquotte, Anne , Crouch, Simon , Sarangi, Vivekananda , Asmann, Yan W. , Offit, Kenneth , Salles, Gilles , Wu, Xifeng , Smedby, Karin E. , Skibola, Christine F., Rothman, Nathaniel , Cocco, Pierluigi , Asmann, Yan, Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Zeleniuch-Jacquotte, Anne , Hildebrandt, Michelle A.T. , Vijai, Joseph , Teras, Lauren R. , Giles, Graham G. , Kraft, Peter , Albanes, Demetrius , Zhang, Yawei , Slager, Susan L. , Chanock, Stephen Jacob , Cerhan, James R.

Mayo Clinic

Human Molecular Genetics | October 1, 2019 | Volume: 29 | Issue: 1 | Pages: 70-79

10.1093/hmg/ddz228 | PMID 31600786 Get It

Abstract We previously identified five single nucleotide polymorphisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (GWAS). To further elucidate genetic susceptibility to DLBCL, we sought to validate two loci at 3q13.33 and 3p24.1 that were suggestive in the original GWAS with additional genotyping. In the meta-analysis (5662 cases and 9237 controls) of the four original GWAS discovery scans and three replication studies, the 3q13.33 locus (rs9831894; minor allele frequency [MAF] = 0.40) was associated with DLBCL risk [odds ratio (OR) = 0.83, P = 3.62 × 10−13]. rs9831894 is in linkage disequilibrium (LD) with additional variants that are part of a super-enhancer that physically interacts with promoters of CD86 and ILDR1. In the meta-analysis (5510 cases and 12 817 controls) of the four GWAS discovery scans and four replication studies, the 3p24.1 locus (rs6773363; MAF = 0.45) was also associated with DLBCL risk (OR = 1.20, P = 2.31 × 10−12). This SNP is 29 426-bp upstream of the nearest gene EOMES and in LD with additional SNPs that are part of a highly lineage-specific and tumor-acquired super-enhancer that shows long-range interaction with AZI2 promoter. These loci provide additional evidence for the role of immune function in the etiology of DLBCL, the most common lymphoma subtype.
“M” line: New anatomical landmark for the maxillary sinus natural ostium
Leite, Janaina Gonçalves da Silva , Nogueira, João Flávio , Pallanch, John F., Costa, Ticiana Cabral da, Feijão, Moisés Ximenes, Querido, Raquel de Sousa Lobo Ferreira, Cavalcante, Maria Luzete Costa , Pallanch, John

Mayo Clinic

Clinical Otolaryngology | October 1, 2019 | Volume: 45 | Issue: 2 | Pages: 177-181

10.1111/coa.13456 | PMID 31574207 Get It

AbstractObjectiveDescribe a reliable anatomical landmark that can be used to locate the maxillary sinus natural ostium (MSNO) during endoscopic surgery, even if the uncinate process is preserved.DesignDescriptive anatomical.SettingAn anatomical and radiological study was performed to evaluate the consistency of the landmark, denominated "M" line.Subjects and MethodsDissections were performed in 57 cadaver heads (114 sides). In addition, 73 computerised tomography (CT) scans (146 sides) of patients with chronic inflammatory sinonasal disease were analysed using a three‐dimensional (3D) reconstruction computer program.ResultsThe "M" line crossed the MSNO in 112 dissected sides (98.2%) and 140 sides at CT 3D reconstruction (95.9%).ConclusionThe "M" line is a reliable anatomical landmark for predicting MSNO location. As such, it could improve and facilitate endoscopic sinus surgery, using traditional, minimally invasive or uncinate preserving techniques.
Gluteal Vein Anatomy: Location, Caliber, Impact of Patient Positioning, and Implications for Fat Grafting
Turin, Sergey Y. , Fracol, Megan , Keller, Eric J. , Markl, Michael , Krochmal, Daniel J., Kim, John Y. S. , Collins, Jeremy, Markl, Michael , Collins, Jeremy D.

Mayo Clinic

Aesthetic Surgery Journal | October 1, 2019 | Volume: 40 | Issue: 6 | Pages: 642-649

10.1093/asj/sjz260 | PMID 31574144 Get It

Abstract Background Deaths in gluteal autografting occur due to gluteal vein injuries, but data are lacking on the precise location and caliber of these veins. Objectives The authors sought to present the first in vivo study of gluteal vein anatomy utilizing magnetic resonance imaging. Methods Magnetic resonance imaging venography of 16 volunteer hemi-sections was conducted in the supine, prone, prone with a bump (jack-knife), and left and right decubitus positions in 1 session after a single contrast administration. Caliber and course of the superior and inferior gluteal veins (SGV/IGV) were analyzed vs bony landmarks and position changes. Results The SGV has a very short submuscular course before splitting into 2 smaller branches superolaterally. The IGV runs immediately deep to the gluteus maximus in the center of the buttock as a single large trunk, on average 56 mm deep (mean 27 mm of muscle belly and 30 mm subcutaneous fat). No intramuscular or subcutaneous branches greater than 2 mm were found. In the prone position, the IGV and SGV have an average caliber of 5.96 mm and 5.63 mm. Vessel caliber decreased by 21% and 27%, respectively, in the jack-knife position and by 14% and 15% in lateral decubitus. Conclusions The SGV and IGV are immediately deep to gluteus maximus approximately 6 cm deep with a caliber on the order of 6 mm in the prone position. The distribution of these vessels suggests there is no “safe zone” in the intramuscular or submuscular planes. The jackknife or lateral decubitus positions can decrease vein caliber by up to 27%, possibly reducing the risk of injury due to either traction or direct cannula impact.
Ethics of Artificial Intelligence in Radiology: Summary of the Joint European and North American Multisociety Statement
Geis, J. Raymond , Brady, Adrian P. , Spencer, Jack , Ranschaert, Erik , Jaremko, Jacob L. , Langer, Steve G., Birch, Judy, Shields, William , Genderen, R. van den Hoven van , Cook, Tessa S. , Morgan, Matthew B. , Tang, An , Safdar, Nabile , Wu, Carol C. , Langer, Steve G., Kitts, Andrea Borondy , Birch, Judy, Shields, William F., Kotter, Elmar , Gichoya, Judy Wawira , Kohli, Marc

Mayo Clinic

Canadian Association of Radiologists Journal | October 1, 2019 | Volume: 70 | Issue: 4 | Pages: 329-334

10.1016/j.carj.2019.08.010 | PMID 31585825 Get It

This is a condensed summary of an international multisociety statement on ethics of artificial intelligence (AI) in radiology produced by the ACR, European Society of Radiology, RSNA, Society for Imaging Informatics in Medicine, European Society of Medical Imaging Informatics, Canadian Association of Radiologists, and American Association of Physicists in Medicine. AI has great potential to increase efficiency and accuracy throughout radiology, but it also carries inherent pitfalls and biases. Widespread use of AI-based intelligent and autonomous systems in radiology can increase the risk of systemic errors with high consequence and highlights complex ethical and societal issues. Currently, there is little experience using AI for patient care in diverse clinical settings. Extensive research is needed to understand how to best deploy AI in clinical practice. This statement highlights our consensus that ethical use of AI in radiology should promote well-being, minimize harm, and ensure that the benefits and harms are distributed among stakeholders in a just manner. We believe AI should respect human rights and freedoms, including dignity and privacy. It should be designed for maximum transparency and dependability. Ultimate responsibility and accountability for AI remains with its human designers and operators for the foreseeable future. The radiology community should start now to develop codes of ethics and practice for AI that promote any use that helps patients and the common good and should block use of radiology data and algorithms for financial gain without those two attributes.
Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity
Koch, Kenneth L. , Hasler, William L. , Natta, Mark L. Van , Calles-Escandón, Jorge, Grover, Madhusudan , Pasricha, Pankaj J. , Snape, William J., Parkman, Henry P. , Abell, Thomas L. , McCallum, Richard W. , Sarosiek, Irene , Farrugia, Gianrico , Tonascia, James , Miriel, Laura , Hamilton, Frank A., Nguyen, Linda A , Hasler, W L , Parkman, H P , Abell, T L , Nguyen, Linda Anh B. , Lee, Linda

Mayo Clinic

Neurogastroenterology & Motility | October 1, 2019 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/nmo.13720 | PMID 31574209 Get It

Abstract Background Symptoms induced by caloric or non‐caloric satiety test meals and gastric myoelectrical activity (GMA) have not been studied in patients with diabetic gastroparesis (DGP) before and after intense glucose management. Aims We determined the effects of continuous subcutaneous insulin infusion (CSII) with continuous glucose monitoring (CGM) on GI symptoms, volume consumed, and GMA induced by the caloric meal satiety test (CMST) and water load satiety test (WLST) in DGP. Methods Forty‐five patients with DGP underwent CMST and WLST at baseline and 24 weeks after CSII with CGM. Subjects ingested the test meals until they were completely full. Visual analog scales were used to quantify pre‐ and postmeal symptoms, and GMA was recorded with cutaneous electrodes and analyzed visually and by computer. Key Results At baseline and 24‐week visits, nausea, bloating, abdominal discomfort, and fullness were immediately increased after CMST and WLST (Ps < 0.01). The meal volumes ingested were significantly less than normal controls at both visits in almost one‐third of the subjects. After the CMST, the percentage 3 cycle per minute GMA increased and bradygastria decreased compared with WLST (Ps < 0.05). After treatment for 24 weeks meal volumes ingested, postmeal symptoms and GMA were no different than baseline. Conclusions and inferences (a) Satiety test meals elicited symptoms of nausea, bloating, and abdominal discomfort; (b) CMST stimulated more symptoms and changes in GMA than WLST; and (c) CSII with CGM for 24 weeks did not improve symptoms, volumes ingested, or GMA elicited by the two satiety test meals in these patients with diabetic GP. Satiety tests in diabetic gastropresis are useful to study acute postprandial symptoms and GMA, but these measures were not improved by intensive insulin therapy.
Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo
Fifield, Amber L. , Hanavan, Paul D., Faigel, Douglas O. , Sergienko, Eduard , Bobkov, Andrey A. , Meurice, Nathalie , Polito, Alysia, Caulfield, Thomas R. , Castle, Erik P., Copland, John A. , Pal, Krishnendu , Dutta, Shamit K., Luo, Huijun , Ho, Thai H. , Lake, Douglas F. , Petit, Joachim L. , Pal, Krishnendu , Ho, Thai , Caulfield, Thomas R , Meurice, Nathalie , Mukhopadhyay, Debabrata

Mayo Clinic

Molecular Cancer Therapeutics | October 1, 2019 | Volume: 19 | Issue: 1 | Pages: 112-122

10.1158/1535-7163.mct-19-0233 | PMID 31575656 Get It

Abstract Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor growth and invasion in vitro and in vivo, we hypothesized that chemical compounds inhibiting QSOX1 enzymatic activity would also suppress tumor growth, invasion, and metastasis. High throughput screening using a QSOX1-based enzymatic assay revealed multiple potential QSOX1 inhibitors. One of the inhibitors, known as “SBI-183,” suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of nonmalignant cells. Oral administration of SBI-183 inhibits tumor growth in 2 independent human xenograft mouse models of renal cell carcinoma. We conclude that SBI-183 warrants further exploration as a useful tool for understanding QSOX1 biology and as a potential novel anticancer agent in tumors that overexpress QSOX1.
Metastatic Spine Disease: Should Patients With Short Life Expectancy Be Denied Surgical Care? An International Retrospective Cohort Study
Dea, Nicolas , Versteeg, Anne , Sahgal, Arjun , Verlaan, Jorrit‐Jan , Charest-Morin, Raphaële , Rhines, Laurence D. , Sciubba, Daniel M. , Schuster, James M. , Weber, Michael H. , Lazáry, Áron , Laufer, Ilya , Gokaslan, Ziya L. , Fisher, Charles G. , Tumor, on behalf of the AOSpine Knowledge Forum, Versteeg, Anne L. , Lazary, Aron , Fehlings, Michael G. , Clarke, Michelle J. , Arnold, Paul M. , Boriani, Stefano , Bettegowda, Chetan , Tumor, on behalf of the AOSpine Knowledge Forum

Mayo Clinic

Neurosurgery | October 1, 2019 | Volume: 87 | Issue: 2 | Pages: 303-311

10.1093/neuros/nyz472 | PMID 31690935 Get It

Abstract BACKGROUND Despite our inability to accurately predict survival in many cancer patients, a life expectancy of at least 3 mo is historically necessary to be considered for surgical treatment of spinal metastases. OBJECTIVE To compare health-related quality of life (HRQOL) in patients surviving <3 mo after surgical treatment to patients surviving >3 mo to assess the validity of this inclusion criteria. METHODS Patients who underwent surgery for spinal metastases between August 2013 and May 2017 were retrospectively identified from an international cohort study. HRQOL was evaluated using generic and disease-specific outcome tools at baseline and at 6 and 12 wk postsurgery. The primary outcome was the HRQOL at 6 wk post-treatment measured by the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ). RESULTS A total of 253 patients were included: 40 patients died within the first 3 mo after surgery and 213 patients survived more than 3 mo. Patients surviving <3 mo after surgery presented with lower baseline performance status. Adjusted analyses for baseline performance status did not reveal a significant difference in HRQOL between both groups at 6 wk post-treatment. No significant difference in patient satisfaction at 6 wk with regard to their treatment could be detected between both groups. CONCLUSION When controlled for baseline performance status, quality of life 6 wk after surgery for spinal metastasis is independent of survival. To optimize improvement in HRQOL for this patient population, baseline performance status should take priority over expected survival in the surgical decision-making process.
Case report: Paradoxical responses to short acting beta-agonists in a pediatric patient
Graden, Alexandra, Gandhi, Sonia , Joshi, Avni Y. , Gandhi, Sonia

Mayo Clinic

Journal of Asthma | October 1, 2019 | Volume: 58 | Issue: 2 | Pages: 213-215

10.1080/02770903.2019.1668009 | PMID 31573361 Get It

Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study
Stang, Cole , Turcano, Pierpaolo , Josephs, Keith A. , Bower, James H., Ahlskog, J. Eric , Martin, Peter R. , Upadhyaya, Sudhindra, Savica, Rodolfo , Stang, Cole D., Upadhyaya, Sudhindra G, Mielke, Michelle M. , Boeve, Bradley F.

Mayo Clinic

Journal of Parkinson’s Disease | October 1, 2019 | Volume: 10 | Issue: 1 | Pages: 179-184

10.3233/jpd-191744 | PMID 31594251 Get It

Background: Few studies have investigated the incidence of PSP and CBS in the population. Objective: To examine the incidence of and trends in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) in a population-based cohort of residents of Olmsted County, MN. Methods: We used the 1991-2005 population-based, Olmsted County Parkinsonism-cohort study, defined via the Rochester Epidemiology Project. A movement-disorder specialist reviewed medical records, to confirm PSP and CBS diagnoses. Results: We identified 21 patients with these diagnoses 1991-2005 : 18 (85.7%), PSP; 3 (14.3%), CBS. The median diagnosis age was 78 (range: 66-88). 13/21 (62.0%) were male. MRI was performed pre-diagnosis in 11 patients (8 PSP and 3 CBD); 10 showed atrophy consistent with clinical diagnoses. We observed concordance between clinical and pathological diagnoses in two PSP patients who underwent autopsy. Combined incidence for PSP and CBS in Olmsted County was 3.1 per 100,000 person-years (2.6 per 100,000 person-years, PSP; 0.4 per 100,000 person-years, CBS). Incidence was higher in men (4.5, 95% CI, 2.0-7.0) than women (1.8, 95% CI, 0.5-2.9). A combined, significant trend of increasing incidence was observed between 1991 and 2005 (B=0.69, 95% CI 0.42, 0.96, p<0.001). Median time from symptom onset to death among both groups was 6 years (range PSP, 1-10 years; range CBS, 3-8 years). Conclusions: The combined incidence for PSP and CBS was 3.1 per 100,000 person-years, higher in men than women. We observed a significant increase in both PSP and CBS, likely due to advancing imaging technology and improved diagnostic ability among physicians.
Supporting the Transition to Practice for Nurse Residents on a Multispecialty Unit
Mangold, Kara , Crockett, Cynthia, Crockett, Cynthia Cindy

Mayo Clinic

Critical Care Nurse | October 1, 2019 | Volume: 39 | Issue: 5 | Pages: 76-79

10.4037/ccn2019165 | PMID 31575598 Get It